Data from No Association of <i>ApoE</i> Genotype with Risk of Prostate Cancer: A Nested Case–Control Study

Abstract

<div>Abstract<p><b>Background:</b> Previous studies found that low total cholesterol level was associated with a lower risk of high-grade prostate cancer. Apolipoprotein E (ApoE) isoform is associated with total cholesterol level. The aim of this study was to explore associations of ApoE isoforms with prostate cancer risk.</p><p><b>Methods:</b> We assessed <i>ApoE</i> genotypes and risk of prostate cancer in a prospective case–control study nested among men who provided a blood sample in 1993–95 within the Health Professionals Follow-up Study. We identified 1,169 incident cases of prostate cancer and 1,233 controls in follow-up through 2004. Associations of ApoE isoform and prostate cancer incidence were evaluated by logistic regression models.</p><p><b>Results:</b> We found no statistically significant associations of <i>ApoE</i> variants with overall prostate cancer or Gleason sum ≤ 7 (3+4), Gleason sum ≥ 7 (4+3), clinically localized stage, or progression to metastasis or death. There was no evidence of effect modification by circulating total cholesterol or use of cholesterol-lowering drugs prior to diagnosis.</p><p><b>Conclusions:</b> <i>ApoE</i> variants were not associated with the risk of prostate cancer or aggressive disease.</p><p><b>Impact:</b> Our findings suggest that the mechanism of circulating cholesterol level affecting prostate cancer incidence may not rely on ApoE isoforms. <i>Cancer Epidemiol Biomarkers Prev; 24(10); 1632–4. ©2015 AACR</i>.</p></div>